Key Points
- Director Barbara Ryan sold 1,300 shares on March 10 at an average price of $15.40 for $20,020, bringing her holdings to 20,406 shares (a 5.99% decrease); she also sold smaller blocks on Mar 9, Mar 2 and Feb 27.
- Shares fell 7.2% to $10.37 on the report with volume of 72,115 (vs. avg ~348,509); MiNK’s market cap is about $48.6M, it has a 52-week range of $6.34–$76.00, and the consensus analyst target is $35 with an average “Hold” rating.
- Institutional activity: DRW Securities bought a new stake of 25,677 shares (~$286,000) in Q4, and hedge funds/institutions own roughly 2.87% of the company.
MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) Director Barbara Ryan sold 1,300 shares of the business's stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $15.40, for a total transaction of $20,020.00. Following the completion of the sale, the director directly owned 20,406 shares of the company's stock, valued at approximately $314,252.40. This trade represents a 5.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Barbara Ryan also recently made the following trade(s):
- On Monday, March 9th, Barbara Ryan sold 200 shares of MiNK Therapeutics stock. The stock was sold at an average price of $10.17, for a total transaction of $2,034.00.
- On Monday, March 2nd, Barbara Ryan sold 100 shares of MiNK Therapeutics stock. The stock was sold at an average price of $10.83, for a total transaction of $1,083.00.
- On Friday, February 27th, Barbara Ryan sold 400 shares of MiNK Therapeutics stock. The shares were sold at an average price of $10.86, for a total transaction of $4,344.00.
MiNK Therapeutics Trading Down 7.2%
Shares of NASDAQ INKT traded down $0.81 during trading hours on Thursday, reaching $10.37. The stock had a trading volume of 72,115 shares, compared to its average volume of 348,509. MiNK Therapeutics, Inc. has a 52-week low of $6.34 and a 52-week high of $76.00. The firm has a market cap of $48.64 million, a price-to-earnings ratio of -3.42 and a beta of 0.35. The business's fifty day moving average price is $11.58 and its two-hundred day moving average price is $12.76.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC purchased a new stake in MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 25,677 shares of the company's stock, valued at approximately $286,000. DRW Securities LLC owned approximately 0.55% of MiNK Therapeutics as of its most recent filing with the SEC. 2.87% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen upgraded MiNK Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $35.00.
Get Our Latest Stock Report on MiNK Therapeutics
About MiNK Therapeutics
(
Get Free Report)
MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company's proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.
MiNK's preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
